What this trial studies
Obesity and other associated complications promote the development and the progression of osteoarthritis. The subcutaneous and abdominal fat release several factors that alter bone and the cartilage. The role of the marrow fat in close connection with bone has not been defined yet, whereas cellular and animal models indicate that this fat depot modifies bone and cartilage. The aim of the study is to define if the marrow fat produces more joint-altering factors by comparison with subcutaneous fat.
Conditions in scope
- Osteoarthritis, Knee
- Prosthesis User
Interventions
- tissue (Procedure) — Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
Who can join
Women only · Ages 18 Years to 85 Years
Inclusion criteria
- Post-menopausal woman
- with a symptomatic knee osteoarthritis requiring prosthesis
- able to handle general anaesthesia
- having given her consent
- able to understand the constraints associated with the study
- with health insurance
- able to understand the French language
Exclusion criteria
- with refusal to participate to the study
- more than 85-year-old
- with bone pathologies other than osteoarthritis or osteoporosis
- with active infection
- with evolving cancer
- with haematopoietic pathologies such as haemoglobin pathologies
- with thyroid pathologies
- with type 1 diabetes
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Lille | Hopital Roger Salengro, CHU Lille | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Observational
- Phase: N/A
- Start date: 2020-06-30
- Primary completion: 2024-03-11
- Last update posted: 2025-12-05
- First posted: 2018-09-20
Sponsor & contact
Lead sponsor: University Hospital, Lille (Other)
Collaborators: MSDAVENIR Foundation
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Expression levels in femoral spinal adipocytes of mRNAs of 18 genes compared to those of adipocytes isolated from the subcutaneous adipose tissue in the same patient (at 3 months)
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT03678831 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.